Conditionally reprogrammed (CRC) and feeder free SMAD inhibited (SMADi) expanded human nasal epithelial cells label-free LC-MS/MS
Ontology highlight
ABSTRACT: Discovery of therapies that are able to correct defective CFTR requires patient derived in vitro pre-clinical cell models to be developed. Two main approaches exist to expand bronchial and nasal cultures, such as conditionally reprogrammed cells (CRC) and feeder free dual SMAD inhibition (SMADi) to overcome senescence, low cell count, and increase passages. To mimic airway epithelium the expanded cells are differentiated at air liquid Interface (ALI). This project focused to compare the global proteome of ALI differentiated CRC and SMADi expanded HNECs both treated and untreated with CFTR corrector VX-809.
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Nasal Epithelium Cell Line, Epithelial Cell
DISEASE(S): Cystic Fibrosis
SUBMITTER: Alexander Capraro
LAB HEAD: Shafagh Waters
PROVIDER: PXD018386 | Pride | 2021-12-05
REPOSITORIES: Pride
ACCESS DATA